Osmotic-Driven Release Kinetics of Bioactive Therapeutic Proteins from a Biodegradable Elastomer are Linear, Constant, Similar, and Adjustable
The aim of the study is to determine whether a biodegradable elastomeric device that uses an osmotic pressure delivery mechanism can release different therapeutic proteins at a nearly constant rate in nanomolar concentrations with high bioactivity, given the same formulation conditions. Vascular endothelial growth factor (VEGF) and interleukin-2 (IL-2) were embedded in the device as sample therapeutic proteins, and their release and bioactivity were compared to that achieved previously with interferon-γ (IFN-γ).
A photo-cross-linkable biodegradable macromer consisting of acrylated star(ɛ-caprolactone-co-d,l-lactide) was prepared. VEGF, IL-2, and IFN-γ were co-lyophilized with serum albumin and trehalose at different ratios and were then embedded into the elastomer by photo-cross-linking the lyophilized particles in a macromer solution. The protein mass and the bioactivity in the release supernatant were measured by enzyme-linked immunosorbent and cell-based assays.
VEGF, IL-2, and IFN-γ were released at the same, nearly constant rate of 25.4 ng/day for over 18 days. Using the optimum elastomer formulation, the release profiles of the proteins were essentially identical, and their rates were linear and constant. Cell-based bioactivity assays showed that 70 and 88% of the released VEGF and IL-2, respectively, were bioactive. The rate of protein release can be adjusted by changing the trehalose loading concentration in the elastomer matrix without altering the linear nature of the protein release kinetics. The elastomeric device degraded in PBS buffer within 85 days.
The elastomer formulation shows promising potential as a sustained protein drug delivery vehicle for local delivery applications.
KeywordsVascular Endothelial Growth Factor Trehalose Therapeutic Protein Protein Release PLGA Microsphere
acrylated star copolymer
vascular endothelial growth factor
The authors thank Norma Turner, Dr. Stephen Pang, and Dr. Yat Tse of Queen's University for their assistance. This research was financially supported by the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada.
- 5.Lee, W. K., Park, J. Y., Yang, E. H., Suh, H., Kim, S. H., Chung, D. S., Choi, K., Yang, C. W., Park, J. S. 2002Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizerJ. Control. Release84115123CrossRefPubMedGoogle Scholar
- 7.Hong, K. D., Ahn, Y. S., Go, J. T., Kim, M. S., Yuk, S. H., Shin, H. S., Rhee, J. M., Khang, G., Lee, H. B. 2005Preparation of double layered nanosphere using dextran and poly(l-lactide-co-glycolide)Polym-Korea29260265Google Scholar
- 8.Cleland, J. L., Duenas, E. T., Park, A., Daugherty, A., Kahn, J., Kowalski, J., Cuthbertson, A. 2001Development of poly-(d,l-lactide–coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesisJ. Control. Release721324CrossRefPubMedGoogle Scholar
- 12.Heller, J., Baker, R. W. 1976System for Delivering Agent to Environment of Use Over Prolonged TimeAlza CorporationUSAGoogle Scholar
- 20.Hughes, C. G., Biswas, S. S., Yin, B. L., Baklanov, O. V., DeGrado, T. R., Coleman, R. E., Donovan, C. L., Lowe, J. E., Landolfo, K. P., Annex, B. H. 1999Intramyocardial but not intravenous vascular endothelial growth factor improves regional perfusion in hibernating porcine myocardiumCirculation100476Google Scholar
- 22.King, T. W., Patrick, C. W. 2000Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(dl-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction techniqueJ. Biomed. Materi. Res.51383390CrossRefGoogle Scholar
- 26.Kavanagh, C. A., Gorelova, T. A., Selezneva, I. I., Rochev, Y. A., Dawson, K. A., Gallagher, W. M., Gorelov, A. V., Keenan, A. K. 2005Poly(N-isopropy acrylamide) copolymer films as vehicles for the sustained delivery of proteins to vascular endothelial cellsJ. Biomed. Materi. Res. A72A2535CrossRefGoogle Scholar
- 33.Rhines, L. D., Sampath, P., DiMeco, F., Lawson, H. C., Tyler, B. M., Hanes, J., Olivi, A., Brem, H. 2003Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant gliomaNeurosurgery52872879CrossRefPubMedGoogle Scholar
- 34.Atkins, T. W., Mccallion, R. L., Tighe, B. J. 1994The incorporation and release of glucose-oxidase and interleukin-2 from a bead formed macroporous hydrophilic polymer matrixJ. Biomater. Sci., Polym. Ed.6651659Google Scholar
- 38.Potgens, A. J., Lubsen, N. H., Altena, M. C., Vermeulen, R., Bakker, A., Schoenmakers, J. G., Ruiter, D. J., Waal, R. M. 1994Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutationsJ. Biol. Chem2693287932885PubMedGoogle Scholar
- 43.Henry, T. D., Rocha-Singh, K., Isner, J. M., Kereiakes, D. J., Giordano, F. J., Simons, M., Losordo, D. W., Hendel, R. C., Bonow, R. O., Eppler, S. M., Zioncheck, T. F., Holmgren, E. B., McCluskey, E. R. 2001Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery diseaseAm. Heart J.142872880CrossRefPubMedGoogle Scholar
- 45.Bocci, V. 1992Physicochemical and biologic properties of interferons and their potential uses in drug delivery systemsCrit. Rev. Ther. Drug Carr. Syst.991133Google Scholar